Research ArticleNEUROPHARMACOLOGY
Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor
Amy C. Porter, John-Michael Sauer, Michael D. Knierman, Gerald W. Becker, Michael J. Berna, Jingqi Bao, George G. Nomikos, Petra Carter, Frank P. Bymaster, Andrea Baker Leese and Christian C. Felder
Journal of Pharmacology and Experimental Therapeutics June 2002, 301 (3) 1020-1024; DOI: https://doi.org/10.1124/jpet.301.3.1020
Amy C. Porter
John-Michael Sauer
Michael D. Knierman
Gerald W. Becker
Michael J. Berna
Jingqi Bao
George G. Nomikos
Petra Carter
Frank P. Bymaster
Andrea Baker Leese
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Journal of Pharmacology and Experimental Therapeutics
Vol. 301, Issue 3
1 Jun 2002
Research ArticleNEUROPHARMACOLOGY
Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor
Amy C. Porter, John-Michael Sauer, Michael D. Knierman, Gerald W. Becker, Michael J. Berna, Jingqi Bao, George G. Nomikos, Petra Carter, Frank P. Bymaster, Andrea Baker Leese and Christian C. Felder
Journal of Pharmacology and Experimental Therapeutics June 1, 2002, 301 (3) 1020-1024; DOI: https://doi.org/10.1124/jpet.301.3.1020
Research ArticleNEUROPHARMACOLOGY
Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor
Amy C. Porter, John-Michael Sauer, Michael D. Knierman, Gerald W. Becker, Michael J. Berna, Jingqi Bao, George G. Nomikos, Petra Carter, Frank P. Bymaster, Andrea Baker Leese and Christian C. Felder
Journal of Pharmacology and Experimental Therapeutics June 1, 2002, 301 (3) 1020-1024; DOI: https://doi.org/10.1124/jpet.301.3.1020
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement